Nanexa AB (publ) (NANEXA.ST)
SEK 2.54
(-5.22%)
SEK 2.54
(-5.22%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 59.15 Million SEK | -743.62% |
| 2022 | 3.4 Million SEK | -21.1% |
| 2021 | 4.31 Million SEK | -79.33% |
| 2020 | 20.85 Million SEK | 138.93% |
| 2019 | 8.73 Million SEK | 110.38% |
| 2018 | 4.14 Million SEK | 27.49% |
| 2017 | 3.25 Million SEK | 60.82% |
| 2016 | 2.02 Million SEK | -8.57% |
| 2015 | 2.21 Million SEK | 80.84% |
| 2014 | 1.22 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -6.18 Million SEK | 407.21% |
| 2024 Q1 | -3.49 Million SEK | 93.18% |
| 2023 Q3 | 13.74 Million SEK | -19.49% |
| 2023 Q4 | -51.26 Million SEK | -472.96% |
| 2023 FY | -21.89 Million SEK | -743.62% |
| 2023 Q1 | 7.01 Million SEK | 142.72% |
| 2023 Q2 | 17.07 Million SEK | 143.41% |
| 2022 Q2 | 86 Thousand SEK | -37.68% |
| 2022 FY | 3.4 Million SEK | -21.1% |
| 2022 Q4 | -16.42 Million SEK | -281.64% |
| 2022 Q3 | 9.04 Million SEK | 10411.63% |
| 2022 Q1 | 138 Thousand SEK | 101.47% |
| 2021 Q2 | 5.09 Million SEK | 2.52% |
| 2021 Q1 | 4.96 Million SEK | -13.33% |
| 2021 FY | 4.31 Million SEK | -79.33% |
| 2021 Q4 | -9.4 Million SEK | -357.43% |
| 2021 Q3 | 3.65 Million SEK | -28.29% |
| 2020 FY | 20.85 Million SEK | 138.93% |
| 2020 Q1 | 3.79 Million SEK | 46.22% |
| 2020 Q3 | 6.36 Million SEK | 28.34% |
| 2020 Q4 | 5.73 Million SEK | -9.97% |
| 2020 Q2 | 4.96 Million SEK | 30.72% |
| 2019 Q2 | 2.86 Million SEK | 132.17% |
| 2019 Q1 | 1.23 Million SEK | -1.01% |
| 2019 FY | 8.73 Million SEK | 110.38% |
| 2019 Q3 | 2.03 Million SEK | -28.97% |
| 2019 Q4 | 2.59 Million SEK | 27.57% |
| 2018 Q3 | 1.01 Million SEK | -43.58% |
| 2018 Q1 | 980 Thousand SEK | -51.09% |
| 2018 Q2 | 1.8 Million SEK | 84.29% |
| 2018 Q4 | 1.24 Million SEK | 22.33% |
| 2018 FY | 4.14 Million SEK | 27.49% |
| 2017 Q2 | 1.38 Million SEK | 133.39% |
| 2017 FY | 3.25 Million SEK | 60.82% |
| 2017 Q4 | 2 Million SEK | 106.99% |
| 2017 Q3 | 968 Thousand SEK | -30.06% |
| 2017 Q1 | 593 Thousand SEK | -44.82% |
| 2016 Q1 | 802 Thousand SEK | 12.26% |
| 2016 Q2 | 576 Thousand SEK | -28.18% |
| 2016 FY | 2.02 Million SEK | -8.57% |
| 2016 Q4 | 1.07 Million SEK | 112.39% |
| 2016 Q3 | 506 Thousand SEK | -12.15% |
| 2015 Q3 | 668 Thousand SEK | -28.86% |
| 2015 Q1 | 71 Thousand SEK | 155.47% |
| 2015 Q2 | 939 Thousand SEK | 1222.54% |
| 2015 Q4 | 714.43 Thousand SEK | 6.95% |
| 2015 FY | 2.21 Million SEK | 80.84% |
| 2014 Q3 | -18 Thousand SEK | 94.93% |
| 2014 FY | 1.22 Million SEK | 0.0% |
| 2014 Q2 | -355 Thousand SEK | 0.0% |
| 2014 Q4 | -127.99 Thousand SEK | -611.07% |
| 2014 Q1 | -355 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AcuCort AB | 6.59 Million SEK | -797.406% |
| AlzeCure Pharma AB (publ) | -476 Thousand SEK | 12527.941% |
| BioGaia AB (publ) | 950.19 Million SEK | 93.774% |
| Enzymatica AB (publ) | 31.86 Million SEK | -85.66% |
| Enorama Pharma AB (publ) | -3.9 Million SEK | 1616.457% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | -9000.00 SEK | 657400.0% |
| Moberg Pharma AB (publ) | -2.09 Million SEK | 2918.342% |
| Newbury Pharmaceuticals AB (publ) | 16.03 Million SEK | -268.97% |
| ODI Pharma AB | -1.34 Million SEK | 4509.321% |
| Orexo AB (publ) | 549.9 Million SEK | 89.242% |
| Probi AB (publ) | 220.21 Million SEK | 73.136% |
| Swedencare AB (publ) | 164.8 Million SEK | 64.104% |
| Swedish Orphan Biovitrum AB (publ) | 14.05 Billion SEK | 99.579% |
| Toleranzia AB | -919 Thousand SEK | 6537.106% |
| Vivesto AB | -10.65 Million SEK | 655.152% |